VYOME HOLDINGS, INC. Foreign Currency Transaction Gain Loss After Tax
VYOME HOLDINGS, INC. (HIND) reported Foreign Currency Transaction Gain Loss After Tax of $41.02 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossAfterTax · last filed 2026-08-12
- VYOME HOLDINGS, INC. foreign currency transaction gain loss after tax for the quarter ending 2026-06-30 was $1.56K, a 12908.33% increase year-over-year.
- VYOME HOLDINGS, INC. foreign currency transaction gain loss after tax for the quarter ending 2026-03-31 was $39.45K, a 3945300.00% increase year-over-year.
- VYOME HOLDINGS, INC. foreign currency transaction gain loss after tax for the quarter ending 2025-12-31 was $10.50K, a 784.67% increase year-over-year.
- VYOME HOLDINGS, INC. foreign currency transaction gain loss after tax for the quarter ending 2025-09-30 was $15.18K.
- VYOME HOLDINGS, INC. foreign currency transaction gain loss after tax for fiscal 2025 was $25.69K, a 2179.86% increase from fiscal 2024.
- VYOME HOLDINGS, INC. foreign currency transaction gain loss after tax for fiscal 2024 was $1.13K.
| Period end | Foreign Currency Transaction Gain Loss After Tax 3 month | Foreign Currency Transaction Gain Loss After Tax 6 month | Foreign Currency Transaction Gain Loss After Tax 9 month | Foreign Currency Transaction Gain Loss After Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $41.02K 10-Q · filed 2026-08-12 | $51.52K derived: sum of 3 quarters · filed 2026-08-12 | $66.70K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $39.45K 10-Q · filed 2026-05-12 | $49.95K derived: sum of 2 quarters · filed 2026-05-12 | $65.14K derived: sum of 3 quarters · filed 2026-05-12 | $65.15K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $10.50K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $25.68K derived: sum of 2 quarters · filed 2026-03-18 | $25.69K derived: sum of 3 quarters · filed 2026-08-12 | $25.69K 10-K · filed 2026-03-18 |
| 2025-09-30 | $15.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $15.19K derived: sum of 2 quarters · filed 2026-08-12 | $15.19K 10-Q · filed 2025-11-14 | $16.38K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $12.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $13.00 10-Q · filed 2026-08-12 | $1.20K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-03-31 | $1.00 10-Q · filed 2026-05-12 | $1.19K derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $1.19K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $1.13K 10-K · filed 2026-03-18 | ||
| 2024-09-30 | -$60.00 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |